Central Sydney GP Network Ltd

ABN 26 093 270 583

Annual Report - 30 June 2022

Central Sydney GP Network Ltd Contents 30 June 2022

Directors' report	2
Auditor's independence declaration	6
Statement of profit or loss and other comprehensive income	7
Statement of financial position	8
Statement of changes in equity	9
Statement of cash flows	10
Notes to the financial statements	11
Directors' declaration	18
Directors' declaration	18
Independent auditor's report to the members of Central Sydney GP Network Ltd	19

General information

The financial statements cover Central Sydney GP Network Ltd as an individual entity. The financial statements are presented in Australian dollars, which is Central Sydney GP Network Ltd's functional and presentation currency.

Central Sydney GP Network Ltd is a not-for-profit unlisted public company limited by guarantee, incorporated and domiciled in Australia. Its registered office and principal place of business is:

EIS Health Limited Level 5 201 Coward Street Mascot NSW 2020

The financial statements were authorised for issue, in accordance with a resolution of directors, on __________ 2022. The directors have the power to amend and reissue the financial statements.

1

Central Sydney GP Network Ltd Directors' report 30 June 2022

The directors present their report, together with the financial statements, on the company for the year ended 30 June 2022.

Directors

The following persons were directors of the company during the whole of the financial year and up to the date of this report, unless otherwise stated:

Dr Margot Woods BMed	Resigned on 26/10/2021
Dr Shereena Sinnayah BMedSci; MBBS(Hons); FRACGP;	29 January 2020- present
DCH; DipDerm Dr Javier Camargo MBBS (UQ), FRACGP, B.PHRM, MAICD, DCH	1 October 2018 – present
Dr Amy Nguyen MBBS, FRACGP	Resigned on 05/08/2021
Dr Evelina Vinchenzo MBChB, DFSRH, DRCOG, MRCGP,	Appointed on 12/06/2021
FRACGP Dr Maryanne Docker MBBS (USYD), DCH (USYD) Dr Thao Nguyen Bsci.MBBS (Hons). Dip Obs. FRACGP	Appointed on 26/10/2021 Appointed on 15/02/2022

Operating results

The deficit of the company amounted to \$81,133 (2021:surplus \$32,350).

Objectives

Short term objectives:

- supporting health professionals to improve the health of local residents
- improving engagement with other key stakeholders
- meeting all contractual obligations of grants
- remaining financially viable.

Long-term objectives:

- supporting members
- representing and advocating for general practice
- remaining financially viable.

Principal activities

The principal activity of Central Sydney GP Network Ltd during the financial year was to administer the objectives of the membership of the Company. For further details refer to Objectives set out above.

No significant changes in the nature of the company's activity occurred during the financial year.

Significant changes in state of affairs

There have been no significant changes in the state of affairs of the company during the year.

Company secretary

Sally Ho appointed as a Company Secretary on 28/06/2021

Matters or circumstances arising after the end of the year

No other matters or circumstances have arisen since the end of the financial year which significantly affected or could significantly affect the operations of the company, the results of those operations or the state of affairs of the company in future financial years.

Information on directors	
Name:	Dr Margot Woods- Resigned on 26/10/2021
Title:	Co-Chair
Experience and expertise:	Has been a GP in the Inner West for nearly 20 years where she set up and ran a multidisciplinary clinic. She also works as a Clinical Editor on Sydney Health Pathways
	and is the Discipline Leader, General Practice, University of Notre Dame.

Central Sydney GP Network Ltd Directors' report 30 June 2022

Name: Title: Experience and expertise:

Dr Shereena Sinnayah

Director

Shereena has been a GP in Sydney's Inner West for the past 8 years.

Shereena involves herself with different aspects of primary care to better understand the role of general practice in our community. In addition to working in a general practice in Erskineville, Shereena also works with Tresillian Family Care Centres supporting local families of children aged 0-3. She remains connected to GP training and education as a Clinical Teaching Visitor with GP Synergy and is a RACGP examiner. She sits on a medical advisory committee for Balmain General Practice Casualty.

Name: Title: Experience and expertise:

Name: Title: Experience and expertise:

Name: Title: Experience and expertise:

Dr Javier Camargo

Co-Chair

Javier has been a full time GP in Sydney's Inner West since 2014. Javier graduated from the University of Queensland in 2010 and completed his post-graduate training at the Royal Brisbane and Women's Hospital and the Royal Children's Hospital, Brisbane. He also holds a degree in Pharmacy and has practised as a pharmacist before completing his medical degree. Javier has undertaken additional training in children's health at Sydney Children's Hospital and in women's health at the Royal Women's Hospital. Javier enjoys all aspects of general practice and in caring for men and women of all ages. He has particular interest in child health, men's health, travel medicine, LGBTQI health, mental health, sexual health and Hepatitis C management. Javier joined the Central Sydney GP network in late 2018 after completing the foundations course in directorship at the Australian Institute of Company Directors. He is keen to use his board appointment as a platform to champion the concerns of GPs in his surrounding network and to advocate for them and liaise with other organisations at different levels to ensure that the concerns of general practitioners is effectively advocated in the delivery of healthcare and to achieve quality general practice which is central to patient care.

Dr Evelina Vinchenzo

Director

Evelina is a local GP based in Leichhardt. Evelina completed her GP training in Manchester, UK before moving to Sydney in 2017. Her special interest is Women's Health and she affiliated with 3 local hospitals to provide GP Antenatal Shared Care. She also teach medical students from The University of Notre Dame, Sydney and take GP registrars. Evelina have been in a leadership role as the Medical Director for my centre of 12 doctors before taking on an appointed role on the CSGPN board in June 2021. She is passionate about General Practice and strongly believe in the role of the CSGPN board as an advocate for GPs. She would love to continue in this role with a view to supporting local GPs through the good, and also more difficult, times. Evelina recognise that the landscape of General Practice is always changing. She is dedicated to staying across current issues and open to listening to the needs of the members, whilst being willing to work hard to try to drive positive changes.

Dr Maryanne Docker

Director

Fellowship of the Royal Australian College of General Practitioners 2001.

Maryanne has a particular interest in managing patients with complex mental health issues. She is acutely aware of the socioeconomic determinants of health and the need to create individual support and services for those who are vulnerable. She is a Shared Care GP for Royal Prince Alfred Hospital. Maryanne particularly enjoys the long term relationships she builds with her patients and being able to provide them with support and medical care through significant life changes. After 20 years of clinic experience and individual patient management, Maryanne hopes to use the skills she has learnt to advocate for and contribute to quality patient health outcomes in our broader healthcare system.

Central Sydney GP Network Ltd Directors' report 30 June 2022

Name: Title: Experience and expertise:

Dr Thao Nguyen

Director

Dr Thao Nguyen graduated with a bachelor of science, bachelor of medicine and bachelor of surgery from the University of UNSW with honours in 2008. She gained experience working across Sydney metropolitan hospitals, undertaking further training in paediatrics, obstetrics and gynaecology at the Royal Hospital for Women and Sydney Children's hospital. She holds a diploma of obstetrics and gynaecology. Dr Nguyen is a fellow of the Royal Australian College of General Practitioners and the Clinical Lead at Clemton Park Family Medical Centre and Crown St Medical Centre. She is also GP Synergy supervisor for GP registrars and an Examiner for the Royal College of General Practitioners.

Thao enjoys teaching and has worked as a tutor and examiner at Notre Dame medical school.

Company secretary

Sally Ho appointed as Company Secretary on 28/06/2021

Meetings of directors

The number of meetings of the company's Board of Directors ('the Board') held during the year ended 30 June 2022, and the number of meetings attended by each director were:

	Full Board	
	Attended	Held
Dr Shereena Sinnayah	3	4
Dr Javier Camargo	4	4
Dr Margot Woods	2	4
Dr Amy Nguyen	1	4
Dr Evelina Vinchenzo	4	4
Dr Thao Nguyen	1	4
Dr Maryanne Docker	2	4

Held: represents the number of meetings held during the time the director held office.

Future developments and results

There are no likely developments expected in the operations of the company that would impact on the expected results of these operations in future financial years.

Member contributions

Central Sydney GP Network Ltd is a company limited by guarantee. In the event of the company being wound up, ordinary members are required to contribute a maximum of \$2 each. Associate members are not required to contribute. The total amount that members of the company are liable to contribute if the company is wound up is \$668, based on 334 ordinary members.

Environmental matters

The company is not subject to any significant environmental regulation under Australian Commonwealth or State law.

Auditor's independence declaration

A copy of the auditor's independence declaration as required in accordance with sub-division 60-40 of the Australian Charities and Not-for-Profit Commission Act 2012, for the year ended 30 June 2022 is set out immediately after this directors' report.

4

This report is made in accordance with a resolution of directors.

On behalf of the directors

DocuSign Envelope ID: 484F8DEE-AAA1-466D-9412-D15EF6A52DD1

Central Sydney GI	P Network Ltd
Directors' report	
30 June 2022	DocuSigned by:

Janier Camargo _____0EEE152A58E648A...

Javier Camargo Director

16 November 2022 | 16:38:09 AEDT

Central Sydney GP Network Ltd Auditor's independence declaration

[This page has intentionally been left blank for the insertion of the auditor's independence declaration]

Central Sydney GP Network Ltd Statement of profit or loss and other comprehensive income For the year ended 30 June 2022

	Note	2022 \$	2021 \$
Revenue	3	808	106,464
Finance income		1,142	2,048
Expenses Employee benefits expense Administration costs Other operating expenses	12 4 _	(52,042) (18,071) (12,970)	(49,669) (15,299) <u>(11,194)</u>
Surplus/(deficit) before income tax expense		(81,133)	32,350
Income tax expense	_		
Surplus/(deficit) after income tax expense for the year	11	(81,133)	32,350
Other comprehensive income for the year, net of tax	_		
Total comprehensive income/(loss) for the year	=	(81,133)	32,350

Central Sydney GP Network Ltd Statement of financial position As at 30 June 2022

	Note	2022 \$	2021 \$
Assets			
Current assets Cash and cash equivalents Trade and other receivables Other assets Total current assets	5 6 8 _	73,276 - 1,875 	100,554 16,500 - 117,054
Non-current assets Financial assets at fair value through profit or loss Total non-current assets	7	733,848	777,164
Total assets	-	808,999	894,218
Liabilities			
Current liabilities Trade and other payables Contract liabilities Total current liabilities	9 10 _	7,872 31,400 39,272	9,458 33,900 43,358
Total liabilities	-	39,272	43,358
Net assets	=	769,727	850,860
Equity Retained surplus	11 _	769,727	850,860
Total equity	=	769,727	850,860

Central Sydney GP Network Ltd Statement of changes in equity For the year ended 30 June 2022

	Retained surplus \$	Total equity \$
Balance at 1 July 2020	818,510	818,510
Surplus after income tax expense for the year Other comprehensive income for the year, net of tax	32,350	32,350
Total comprehensive income for the year	32,350	32,350
Balance at 30 June 2021	850,860	850,860
	Retained surplus \$	Total equity \$
Balance at 1 July 2021	surplus	
Balance at 1 July 2021 Deficit after income tax expense for the year Other comprehensive income for the year, net of tax	surplus \$	\$ 850,860
Deficit after income tax expense for the year	surplus \$ 850,860	\$ 850,860 (81,133)

Central Sydney GP Network Ltd Statement of cash flows For the year ended 30 June 2022

	Note	2022 \$	2021 \$
Cash flows from operating activities Cash receipts from continuing operations Cash paid to suppliers and officers Interest received	-	64,576 (92,417) 1,142	96,313 (86,097) 2,048
Net cash from/(used in) operating activities	-	(26,699)	12,264
Cash flows from investing activities Payments for investments Proceeds from disposal of investments Net cash used in investing activities	-	(92,841) 92,262 (579)	(370,580) 39,311 (331,269)
Cash flows from financing activities	-		
Net cash from financing activities	-		
Net decrease in cash and cash equivalents Cash and cash equivalents at the beginning of the financial year	-	(27,278) 100,554	(319,005) 419,559
Cash and cash equivalents at the end of the financial year	5	73,276	100,554

Note 1. Significant accounting policies

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The company has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

The following Accounting Standards and Interpretations are most relevant to the company:

AASB 1060 General Purpose Financial Statements - Simplified Disclosures for For-Profit and Not-for-Profit Tier 2 Entities The company has adopted AASB 1060 from 1 July 2021. The standard provides a new Tier 2 reporting framework with simplified disclosures that are based on the requirements of IFRS for SMEs. As a result, there is increased disclosure in these financial statements for key management personnel, related parties and financial instruments.

Basis of preparation

These general purpose financial statements have been prepared in accordance with the Australian Accounting Standards -Simplified Disclosures issued by the Australian Accounting Standards Board ('AASB'), the Australian Charities and Not-forprofits Commission Act 2012 and New South Wales legislation the Charitable Fundraising Act 1991 and associated regulations and the Corporations Act 2001, as appropriate for not-for profit oriented entities.

Historical cost convention

The financial statements have been prepared under the historical cost convention.

Critical accounting estimates

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 2.

Contract liability (unearned income) for member subscriptions not a difficult area of estimation and the investments FV is advised by the third party managers so no estimation/judgement by client involved.

Comparative amounts

Comparatives figures have been adjusted to confirm to changes in the presentation for the current financial year where required by accounting standards or as a result of a change in accounting policy.

Going concern

The financial report has been prepared on the going concern basis. The company believes that with continuous support from the members in the form of membership revenue they can continue as a going concern.

The following accounting policies are most relevant to the company:

Revenue recognition

The company recognises revenue as follows:

Revenue from contracts with customers

Revenue is recognised at an amount that reflects the consideration to which the company is expected to be entitled in exchange for transferring goods or services to a customer. For each contract with a customer, the company: identifies the performance obligations in the contract; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to be delivered; and recognises revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised.

Note 1. Significant accounting policies (continued)

Variable consideration within the transaction price, if any, reflects concessions provided to the customer such as discounts, rebates and refunds, any potential bonuses receivable from the customer and any other contingent events. Such estimates are determined using either the 'expected value' or 'most likely amount' method. The measurement of variable consideration is subject to a constraining principle whereby revenue will only be recognised to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. The measurement constraint continues until the uncertainty associated with the variable consideration is subsequently resolved. Amounts received that are subject to the constraining principle are recognised as a refund liability.

Membership income

Membership subscription revenue is recognised upon the receipt of membership renewal applications. Any revenue received during the current financial year that relates to the next financial year is deferred as a contract liability.

All revenue is stated net of the amount of goods and services tax (GST).

Interest

Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

Other revenue

Other revenue is recognised when sales invoices are raised following the performance of service.

Income tax

As the company is a charitable institution in terms of subsection 50-5 of the Income Tax Assessment Act 1997, as amended, it is exempt from paying income tax.

Current and non-current classification

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the company's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the company's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

Cash and cash equivalents

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

Trade and other receivables

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for settlement within 30 days.

The company has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

Note 1. Significant accounting policies (continued)

Investments and other financial assets

Investments and other financial assets are initially measured at fair value. Transaction costs are included as part of the initial measurement, except for financial assets at fair value through profit or loss. Such assets are subsequently measured at either amortised cost or fair value depending on their classification. Classification is determined based on both the business model within which such assets are held and the contractual cash flow characteristics of the financial asset, unless an accounting mismatch is being avoided.

Financial assets are derecognised when the rights to receive cash flows have expired or have been transferred and the company has transferred substantially all the risks and rewards of ownership. When there is no reasonable expectation of recovering part or all of a financial asset, its carrying value is written off.

Financial assets at fair value through profit or loss

Financial assets not measured at amortised cost or at fair value through other comprehensive income are classified as financial assets at fair value through profit or loss. Typically, such financial assets will be either: (i) held for trading, where they are acquired for the purpose of selling in the short-term with an intention of making a profit, or a derivative; or (ii) designated as such upon initial recognition where permitted. Fair value movements are recognised in profit or loss.

Impairment of financial assets

The company recognises a loss allowance for expected credit losses on financial assets which are either measured at amortised cost or fair value through other comprehensive income. The measurement of the loss allowance depends upon the company's assessment at the end of each reporting period as to whether the financial instrument's credit risk has increased significantly since initial recognition, based on reasonable and supportable information that is available, without undue cost or effort to obtain.

Where there has not been a significant increase in exposure to credit risk since initial recognition, a 12-month expected credit loss allowance is estimated. This represents a portion of the asset's lifetime expected credit losses that is attributable to a default event that is possible within the next 12 months. Where a financial asset has become credit impaired or where it is determined that credit risk has increased significantly, the loss allowance is based on the asset's lifetime expected credit losses. The amount of expected credit loss recognised is measured on the basis of the probability weighted present value of anticipated cash shortfalls over the life of the instrument discounted at the original effective interest rate.

For financial assets mandatorily measured at fair value through other comprehensive income, the loss allowance reduces the asset's carrying value with a corresponding expense recognised in other comprehensive income. In all other cases, the loss allowance reduces the asset's carrying value with a corresponding expense through profit or loss.

Trade and other payables

These amounts represent liabilities for goods and services provided to the company prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

Contract liabilities

Contract liabilities represent the company's obligation to transfer goods or services to a customer and are recognised when a customer pays consideration, or when the company recognises a receivable to reflect its unconditional right to consideration (whichever is earlier) before the company has transferred the goods or services to the customer.

Fair value measurement

When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market.

Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

Note 1. Significant accounting policies (continued)

Goods and Services Tax ('GST') and other similar taxes

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST receivable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

Note 2. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) in the current or future financial years are discussed below.

Coronavirus (COVID-19) pandemic

Judgement has been exercised in considering the impacts that the Coronavirus (COVID-19) pandemic has had, or may have, on the company based on known information. This consideration extends to the nature of the products and services offered, customers, supply chain, staffing and geographic regions in which the company operates. Other than as addressed in specific notes, there does not currently appear to be either any significant impact upon the financial statements or any significant uncertainties with respect to events or conditions which may impact the company unfavourably as at the reporting date or subsequently as a result of the Coronavirus (COVID-19) pandemic.

Allowance for expected credit losses

The allowance for expected credit losses assessment requires a degree of estimation and judgement. It is based on the lifetime expected credit loss, grouped based on days overdue, and makes assumptions to allocate an overall expected credit loss rate for each group. These assumptions include recent sales experience and historical collection rates.

Note 3. Revenue

	2022 \$	2021 \$
Revenue from contracts with customers		
Sponsorship income	2,955	1,273
Member subscriptions	40,200	37,200
	43,155	38,473
Other revenue		
Donations received	1,550	620
Net distribution received from financial assets	16,583	18,184
Net change in fair value of financial assets through profit or loss	(60,480)	44,187
Cash flow boost	-	5,000
	(42,347)	67,991
Revenue	808	106,464

Note 4. Other operating expenses

	2022 \$	2021 \$
Recruitment, training and development costs Meetings and venue hire	2,982 3,068	- 1,468
Audit fees Consultancy charges	6,920 	4,726 5,000
	12,970	11,194
Note 5. Cash and cash equivalents		
	2022 \$	2021 \$
<i>Current assets</i> Cash at bank and in hand	73,276	100,554
Note 6. Trade and other receivables		
	2022 \$	2021 \$
<i>Current assets</i> Trade receivables	<u> </u>	16,500
Note 7. Financial assets at fair value through profit or loss		
	2022 \$	2021 \$
Non-current assets Investments	733,848	777,164

Investments comprise of unit trust accounts and are measured at externally quoted market values.

Note 8. Other assets

	2022 \$	2021 \$
<i>Current assets</i> Prepayments	1,875	
Note 9. Trade and other payables		
	2022 \$	2021 \$
<i>Current liabilities</i> GST payable Other payables	1,789 6,083	3,353 6,105
	7,872	9,458

Note 10. Contract liabilities

	2022 \$	2021 \$
<i>Current liabilities</i> Contract liabilities	31,400	33,900
Note 11. Retained surplus		
	2022	2021
	\$	\$
Retained surplus at the beginning of the financial year Surplus/(deficit) after income tax expense for the year	\$ 850,860 (81,133)	\$ 818,510 <u>32,350</u>

Note 12. Key management personnel disclosures

Any person(s) having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including any director of the Company is considered key management personnel (KMP). The total remuneration paid to KMP of the company during the year are as follows:

Total remuneration paid or payable \$52,042 (2021: \$49,669). This includes \$52,042 (2021: \$49,669) paid to the directors of the company.

Note 13. Contingent liabilities

In the opinion of the Directors, the company did not have any contingent liabilities at 30 June 2022 (30 June 2021: none)

Note 14. Related party transactions

Key management personnel

Disclosures relating to key management personnel are set out in note 12.

Transactions with related parties

Transactions between related parties are on normal commercial terms and conditions no more favourable than those available to other parties unless otherwise stated.

The following transactions occurred with related parties:

	2022 \$	2021 \$
Payment for other expenses: Management fees to EIS Health Limited	10,050	9,300
Receivable from and payable to related parties The following balances are outstanding at the reporting date in relation to transactions with i	elated parties:	

	2022 \$	2021 \$
Current receivables: Trade receivables from EIS	-	16,500

Loans to/from related parties

There were no loans to or from related parties at the current and previous reporting date.

Note 14. Related party transactions (continued)

Terms and conditions

All transactions were made on normal commercial terms and conditions and at market rates.

Note 15. Remuneration of auditors

During the financial year the following fees were paid or payable for services provided by the auditor of the company:

	2022 \$	2021 \$
Audit services - Audit of the financial statements	6,080	5,500

Note 16. Events after the reporting period

No matter or circumstance has arisen since 30 June 2022 that has significantly affected, or may significantly affect the company's operations, the results of those operations, or the company's state of affairs in future financial years.

Note 17. Company Details

The registered office of the company is:

Central Sydney GP Network Ltd Tower A Level 5, 201 Coward Street Mascot NSW 2020

Central Sydney GP Network Ltd Directors' declaration 30 June 2022

In the directors' opinion:

- the attached financial statements and notes comply with the Australian Accounting Standards Simplified Disclosure, the Australian Charities and Not-for-profits Commission Act 2012 and New South Wales legislation the Associations Incorporation Act 2009, the Charitable Fundraising Act 1991 and associated regulations;
- the attached financial statements and notes give a true and fair view of the company's financial position as at 30 June 2022 and of its performance for the financial year ended on that date; and
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors.

On behalf of the directors

-Docusigned by: Javier Camargo 16 November 2022 | 16:38:09 AEDT

Javier Camargo Director Central Sydney GP Network Ltd Independent auditor's report to the members of Central Sydney GP Network Ltd

[This page has intentionally been left blank for the insertion of page one of the independent auditor's report]

Central Sydney GP Network Ltd Independent auditor's report to the members of Central Sydney GP Network Ltd

[This page has intentionally been left blank for the insertion of page two of the independent auditor's report]